CombiMatrix Announces Contract With Galaxy Health Network
23 Enero 2014 - 5:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for
developmental disorders and cancer diagnostics, today announced
that it has entered into a contractual agreement with Galaxy Health
Network for coverage of CombiMatrix's diagnostic laboratory
services.
Galaxy Health Network, based in Arlington, TX, has a provider
base of more than 400,000 directly contracted physicians, 2,700
hospitals and 47,000 ancillary providers. Its member base has
currently more than 3.5 million covered lives. These members now
have access to CombiMatrix's suite of molecular diagnostic
solutions and comprehensive clinical support – specializing in
prenatal, miscarriage and pediatric healthcare.
Mark McDonough, President and Chief Executive Officer of
CombiMatrix, noted that the partnership with Galaxy is another
opportunity for CombiMatrix to broaden its payor geographic reach.
"This agreement further expands our reach throughout the country
providing much wider access to our entire portfolio of testing
services, including our CombiSNP chromosomal microarray test.
"Our partnership with Galaxy allows us to jointly educate
physicians in the Galaxy network about the advantages of
chromosomal microarray testing," McDonough said. "We believe our
services are a vital addition to important health networks like
Galaxy and look forward to a significant and growing commercial and
clinical relationship."
About Galaxy Health Network
Privately-held Galaxy Health Network was founded as Managed Care
Inc. in 1993 through the purchase of the assets of AUGNET, a
California-based Preferred Provider Organization. In 1998, Managed
Care Inc changed the name of its provider network to Galaxy Health
Network. Today, Galaxy Health Network has grown its provider base
to over 400,000 physicians, 2,700 hospitals and 47,000 ancillary
providers – all directly contracted, and brings together Managed
Care Professionals with over five decades of collective experience
for the purpose of providing expert assistance and guidance in the
containment of medical costs.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care – specializing in miscarriage analysis, prenatal
and pediatric healthcare. CombiMatrix offers comprehensive testing
services for the detection of genetic abnormalities at the DNA
level, beyond what can be identified through traditional
methodologies. The Company performs genetic testing utilizing
advanced technologies, including microarray, FISH, PCR and G-Band
chromosome analyses. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can often be
identified by words such as "anticipates," "expects," "intends,"
"plans," "goal," "predicts," "believes," "seeks," "estimates,"
"may," "will," "should," "would," "could," "potential," "continue,"
"ongoing," "objective," similar expressions, and variations or
negatives of these words and include, but are not limited to,
statements regarding the access to our services for Galaxy Health
Network physicians. These forward-looking statements are not
guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause our actual results
to differ materially and adversely from those expressed in any
forward-looking statement The risks and uncertainties referred to
above include, but are not limited to: use of our services by
Galaxy Health Network physicians; market acceptance of CMA as a
superior method of molecular diagnostic testing; our ability to
successfully expand the base of our customers and strategic
partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related
reports, optimize the reimbursements received for our testing
services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to
successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer
rosters in both developmental medicine and oncology; our ability to
attract and retain a qualified sales force; rapid technological
change in our markets; changes in demand for our future products;
legislative, regulatory and competitive developments; general
economic conditions; and various other factors. Further information
on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and Exchange
Commission. We undertake no obligation to revise or update publicly
any forward-looking statements for any reason, except as required
by law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Investor Contact:
Matt Clawson
Partner
Allen & Caron
Tel (949) 474-4300
Matt@allencaron.com
Media Contact:
Len Hall
VP, Media Relations
Allen & Caron
Tel (949) 474-4300
len@allencaron.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024